| Code | CSB-RA004913MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of lulizumab pegol (BMS-931699), targeting CD28, one of the most important co-stimulatory receptors on T lymphocytes. CD28 engagement by CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells provides the classic “signal 2” that amplifies TCR signaling, supporting T-cell activation, proliferation, and cytokine programs (notably IL-2) and shaping effector vs regulatory T-cell outcomes.
Lulizumab pegol is described as a human anti-CD28 receptor antagonist built in a monovalent “domain antibody (dAb)” format and PEGylated (reported as a 40-kDa branched PEG conjugate) to extend half-life while minimizing CD28 crosslinking risks that can occur with conventional bivalent anti-CD28 antibodies. As a selective CD28 blockade approach, it is positioned to inhibit CD28-mediated co-stimulation while preserving the CD80/86–CTLA-4 co-inhibitory axis, enabling researchers to dissect CD28-dependent activation biology and immune “rheostat” mechanisms in controlled systems. This biosimilar supports studies on T-cell activation thresholds, costimulation blockade pharmacology, and Treg/Teff balance, as well as assay development where CD28 pathway modulation is the primary variable.
There are currently no reviews for this product.